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A B S T R A C T
Type 2 diabetes mellitus (T2DM) is associated with a higher risk of cancer and cancer-related mortality.
Increased blood glucose and insulin levels in T2DM patients may be, at least in part, responsible for this effect.
Indeed, lowering glucose and/or insulin levels pharmacologically appears to reduce cancer risk and progression,
as has been demonstrated for the biguanide metformin in observational studies. Studies investigating the in-
fluence of sulfonylurea derivatives (SUs) on cancer risk have provided conflicting results, partly due to com-
parisons with metformin. Furthermore, little attention has been paid to within-class differences in systemic and
off-target effects of the SUs. The aim of this systematic review is to discuss the available preclinical and clinical
evidence on how the different SUs influence cancer development and risk. Databases including PubMed,
Cochrane, Database of Abstracts on Reviews and Effectiveness, and trial registries were systematically searched
for available clinical and preclinical evidence on within-class differences of SUs and cancer risk. The overall
preclinical and clinical evidence suggest that the influence of SUs on cancer risk in T2DM patients differs be-
tween the various SUs. Potential mechanisms include differing affinities for the sulfonylurea receptors and thus
differential systemic insulin exposure and off-target anti-cancer effects mediated for example through potassium
transporters and drug export pumps. Preclinical evidence supports potential anti-cancer effects of SUs, which are
of interest for further studies and potentially repurposing of SUs. At this time, the evidence on differences in
cancer risk between SUs is not strong enough to guide clinical decision making.
1. Introduction
Patients diagnosed with type 2 diabetes mellitus (T2DM) have an
increased risk of cancer and cancer-related mortality (Chen et al.,
2017b; Giovannucci et al., 2010). This increased risk is already present
before diagnosis of T2DM (de Kort et al., 2017; Redaniel et al., 2012;
Schrijnders et al., 2018; Yu et al., 2016). T2DM is characterized by
insulin resistance, hyperglycemia and hyperinsulinemia, which have all
been associated with cancer development (Jalving et al., 2010; Yang
et al., 2010a. Cancer cells have an altered energy metabolism char-
acterized by high glucose consumption and high glycolysis rates. This
provides energy to generate ATP as well as metabolic intermediates for
production of biomass required for cellular proliferation (Liberti and
Locasale, 2016). This so-called metabolic reprogramming is one of the
hallmarks of cancer (Hanahan and Weinberg, 2011). The metabolic
characteristics of tumors and their microenvironment are increasingly
important for understanding cancer development, treatment resistance
and for the identification of novel treatment targets (Pavlova and
Thompson, 2016). Therefore, investigation of factors associated with
cancer development in T2DM patients is of particular interest.
Increased plasma glucose and insulin levels are, at least in part,
responsible for the increased risk of cancer and cancer related mortality
of T2DM patients (Ariaans et al., 2015). The various classes of glucose-
lowering agents have different mechanisms of action, and thus differ-
ential effects on plasma glucose and insulin levels and different off-
target effects. Therefore, these classes of drugs may also differ in their
influence on cancer risk and development. Preclinical studies in cancer
models and observational clinical evidence indicate anti-cancer effects
of the biguanide metformin and clinical trials testing effectivity of
metformin in cancer patients are ongoing (Jalving et al., 2010; Soranna
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et al., 2012). For the other important class of oral glucose lowering
drugs, the sulfonylurea derivatives (SUs), available data is conflicting
(Chen et al., 2017a; Currie et al., 2013; Hsieh et al., 2012; Mamtani
et al., 2014; Morgan et al., 2012; Qiu et al., 2013). Several studies have
reported an association between increased cancer risk and use of SUs in
T2DM patients, in some cases potentially confounded by the use of
metformin as a comparator (Chen et al., 2017a; Thakkar et al., 2013;
Yang et al., 2010a). Other studies have shown that SU use did not in-
crease cancer risk in T2DM patients (Calip et al., 2016; Thakkar et al.,
2013) or even decreased cancer risk (Häggström et al., 2017) compared
to T2DM patients not using SUs. The conflicting data regarding the
effects of SUs on cancer risk and development may be the result of
differential effects of the individual SUs in terms of systemic or off-
target effects.
The aim of this systematic review is to discuss the available pre-
clinical and clinical evidence on differences in cancer risk and devel-
opment between patients treated with different SU drugs.
Understanding these so-called within-SU class differences is important
to understand the conflicting data regarding cancer risk of SUs and to
determine whether sufficient data is available to guide clinical selection
of SUs for glycemic control. In addition, the accumulated preclinical
and clinical evidence of the differential effects of SUs on cancer risk in
T2DM patients may help to identify novel cancer treatment targets.
2. Search strategy
For clinical studies, databases including Medline (using PubMed),
Cochrane, Database of Abstracts on Reviews and Effectiveness, and
several trial registries (last search update March 21st, 2019, see sup-
plementary file S1 for the complete search strategy) were searched for
relevant meta-analyses, randomized trials, case-control studies and
observational studies by two authors. Acetohexamide and tolazamide
were excluded from the search, since these SUs are currently not re-
gistered in Europe or the United States of America. Studies that in-
vestigated cancer incidence in T2DM patients and compared individual
SUs to each other were eligible for selection. Title and abstract were
screened by two authors and full text articles were selected. See sup-
plementary file S1 for detailed information on search strategy for
clinical data and Fig. S1 for the flow chart of data extraction.
For preclinical data, separate searches were performed for the eight
different SUs in Medline (using PubMed) combined with the terms
“cancer OR tumor* OR tumour*”. Based on the abstracts, relevant ar-
ticles on the effects of SUs on cancer cell growth and intracellular
mechanisms in preclinical models of cancer were selected by two au-
thors. Relevant references of the selected articles were also searched.
Articles written in languages other than English were excluded. Only
original papers were included.
3. Differences between SUs in blood glucose lowering capacity
Increased glucose and insulin levels have cancer initiating and
growth stimulatory effects in preclinical cancer models (Ariaans et al.,
2015). Therefore, SUs that consistently normalize blood glucose levels
with minimal systemic insulin exposure, e.g. by a specific meal de-
pendent insulin release, are most likely to show benefit in terms of
reducing relative cancer risk. SUs are grouped into three generations
(Table 1), which differ with respect to strength of glucose-lowering
capacity, side-effects and the presence of active metabolites. Target
molecules for SUs are the sulfonylurea receptors, which are subunits of
ATP-sensitive potassium channels (K+ATP channel) (Fig. 1) (Nichols,
2006). The different SUs have varying affinities for the sulfonylurea
receptor isoforms and differ in hypoglycemia risk (Table 1). No severe
hypoglycemia cases have been reported for gliclazide users, in contrast
to the other SUs (Chan and Colagiuri, 2015; Holstein et al., 2010,
2001).
Extra-pancreatic blood glucose lowering effects of SUs in humans
have also been described (Beck-Nielsen et al., 1988; DeFronzo and
Simonson, 1984; Kolterman, 1987), however the available studies are
small and not all SUs have been investigated, nor were different SUs
compared within clinical studies. In dogs, glibenclamide was shown to
have a lower extra-pancreatic blood glucose-lowering capacity than
glimepiride (Müller et al., 1995). Postulated mechanisms for the extra-
pancreatic effects include effects on hepatic glycogen metabolism,
gluconeogenesis and lipogenesis. However, these mechanisms have
mostly been studied at varying, often supra-physiological, drug con-
centrations and have not been studied in humans (Beck-Nielsen et al.,
1988; Feldman and Lebovitz, 1969; Müller et al., 1995).
4. Differences between SUs in cancer risk: clinical evidence
The search strategy for the clinical studies yielded six eligible stu-
dies (Fig. S1) (Bo et al., 2013; Chang et al., 2012; Monami et al., 2007,
2009; Tuccori et al., 2015; Yang et al., 2010a), of which three retro-
spective (Bo et al., 2013; Monami et al., 2007; Tuccori et al., 2015) and
three prospective (Chang et al., 2012; Monami et al., 2009; Yang et al.,
2010a) (Table 2). All studies included patients with varying durations
of diabetes and the mean follow-up periods ranged from 4.8 to 14 years.
Five of the six studies focused on all-cancer incidence (Bo et al., 2013;
Chang et al., 2012; Monami et al., 2007; Tuccori et al., 2015; Yang
et al., 2010a) and one reported both all-cancer and site-specific cancer
incidence (Monami et al., 2009). Two of the six studies had all-cancer
mortality as primary outcome (Bo et al., 2013; Monami et al., 2007)
and the other four had cancer incidence as primary outcome. Three of
the six studies investigated dose-response relationships for individual
SUs (Chang et al., 2012; Tuccori et al., 2015; Yang et al., 2010a) and
one of the six studies investigated treatment duration-response differ-
ences for individual SUs (Monami et al., 2009). One study incorporated
a time-varying design, taking changes in covariates during follow-up
into account (Tuccori et al., 2015). In these six studies, data on cancer
risk was found for gliclazide, glimepiride, glibenclamide and tolbuta-
mide use; no data was found for the other SUs of interest (chlorpro-
pramide and glipizide).
4.1. Gliclazide
Clinical evidence regarding effects of gliclazide use on cancer risk
and development was described in three studies. In a retrospective
observational study (n= 1277) with a mean follow-up of 14 years,
T2DM patients treated with gliclazide had a lower cancer mortality risk
(hazard ratio (HR) 0.30, 95% confidence interval (CI) 0.16–0.55)
compared to glibenclamide treated patients (Bo et al., 2013). The
analyses were adjusted for metformin and insulin use, age, sex, body-
mass index (BMI), smoking, diabetes duration, anti-hypertensive
therapy, glycated hemoglobin (HbA1c), presence of retinopathy, neu-
ropathy and cardiovascular diseases.
The second study had a prospective design including 6103 patients
and showed that 'ever use' compared to 'never use' of gliclazide was
associated with a lower cancer risk (HR 0.65, 95%CI 0.49–0.83) in a
dose dependent matter in the ever group (Yang et al., 2010a). Ever use
was defined as use of gliclazide at, or within 2.5 years before, enrol-
ment or during follow-up period. Outcomes were adjusted for age, sex,
BMI, smoking, alcohol use, baseline HbA1c, systolic blood pressure,
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, triglyceride, and ever use of statins, renin-angio-
tensin system inhibitors, metformin and insulin. This study did not
correct for HbA1c levels of patients during follow-up.
The third study was a prospective, case-control study including 195
cases with cancer and 195 cases without cancer matched for age, sex,
duration of diabetes, BMI, HbA1c, comorbidity, smoking and alcohol
use (Monami et al., 2009). This study showed that T2DM patients using
gliclazide for at least 12 months (odds ratio (OR) 0.39, 95%CI
0.21–0.74) and for at least 36 months (OR 0.40, 95%CI 0.23–0.69) had
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a lower cancer risk compared to patients who had never used gliclazide.
The analyses were adjusted for other glucose lowering treatments. Due
to the limited cohort sizes, no separate HRs for specific cancer types
were calculated.
4.2. Glibenclamide
Clinical evidence regarding effects of glibenclamide use on cancer
risk and development was described in four studies. The first study had
a prospective design including 6103 patients and showed that 'ever use'
compared to 'never use' was associated with a lower cancer risk (HR
0.67, 95%CI 0.51–0.89) in a dose-dependent manner in the ever group
(Yang et al., 2010a). Ever use was defined as use of glibenclamide at, or
within 2.5 years before, enrolment or during the follow-up period.
Outcomes were adjusted for age, sex, BMI, smoking, alcohol use,
baseline HbA1c, systolic blood pressure, LDL-cholesterol related risks,
HDL-cholesterol, triglyceride, and ever use of statins, renin-angiotensin
system inhibitors, metformin and insulin. This study did not correct for
HbA1c levels of patients during follow-up.
In contrast, the second study described a retrospective analysis in-
volving 52,600 SU-naïve T2DM patients starting SU use between 1
January 1988 and 31 July 2013 with a mean follow-up of 5.3 years
(Tuccori et al., 2015). Glibenclamide use was not associated with a
change in risk of developing cancer compared to other second gen-
eration SUs (HR 1.09, 95%CI 0.98–1.22) (Tuccori et al., 2015). How-
ever, for a high cumulative dose (> 1096 drug consumptions of the
daily defined dose) of glibenclamide, a dose-dependent higher cancer
risk was found compared to other second generation SUs (HR 1.27,
95%CI 1.06–1.51) (Tuccori et al., 2015). Results were adjusted for year
of cohort entry, age, sex, BMI, smoking, alcohol use, HbA1c before
study cohort entry, duration of treated diabetes before study cohort
entry, ever use of other anti-diabetic drugs before study cohort entry
(including first-generation SUs), and ever use of aspirin, statins and
non-steroidal anti-inflammatory drugs. Strong points of this study were
that both duration of SU use and the dose were taken into account, and
a time-dependent analysis of exposure to SUs was incorporated.
Similarly, another study also described an association between
glibenclamide use and higher cancer risk. This study was a prospective,
case-control study including 195 cases with cancer and 195 cases
without cancer matched for age, sex, duration of diabetes, BMI, HbA1c,
comorbidity, smoking and alcohol use (Monami et al., 2009). This study
showed that the OR for malignancies after exposure to glibenclamide
for at least 12 and at least 36 months was 2.24 (95%CI 1.21–4.14) and
Fig. 1. Schematic representation of the mechanism of action of sulfony-
lurea derivatives (SUs) on a β-cell of the pancreas. ADP: adenosine dipho-
sphate; ATP: adenosine triphosphate; Ca2+: calcium; GLUT-2: glucose trans-
porter 2; K+: potassium; SUR-1: sulfonylurea receptor 1. The numbered boxes
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2.62 (95%CI 1.26–5.42), respectively, compared to no exposure to
glibenclamide (Monami et al., 2009). The analyses were adjusted for
other oral glucose lowering treatments. The number of patients in this
study is relatively small.
Lastly, a retrospective study (n= 568) with a mean follow-up of 5
years, described a higher all-cancer mortality in glibenclamide users
compared to gliclazide users (OR 3.6, 95%CI 1.1–11.9) (Monami et al.,
2007). This analysis was corrected for age, sex, BMI, insulin and met-
formin treatment. No dose response or cumulative duration analyses
were performed and the analysis was not adjusted for HbA1c.
4.3. Glimepiride
In a case-control study, 108,920 newly diagnosed T2DM patients
were identified (Chang et al., 2012). From this cohort, 8194 cancer
cases and 32,776 age- and sex-matched diabetic controls with a mean
diabetes duration of 3.6 years and a median follow-up of 7.4 years were
included in the analyses (Chang et al., 2012). Use of glimepiride com-
pared to ‘non-use’ did not increase overall cancer risk (OR 1.00, 95%CI
0.93–1.08) in newly-diagnosed diabetes patients (Chang et al., 2012). It
is not clear whether the 'non-use' group included patients using no
medication at all or patients not using glimepiride. The remaining non-
glimepiride SUs were grouped together as first/second generation SUs
and showed an increased cancer risk compared to ‘non-use’ (OR 1.08,
95%CI 1.01–1.15) (Chang et al., 2012). No dose-response or duration
response relationships for any SUs were found (Chang et al., 2012). The
analyses were adjusted for many covariates including insulin, SUs,
glinides, metformin, thiazolidinediones, α-glucosidase inhibitors, sta-
tins, β-blockers, calcium channel blockers, angiotensin-converting en-
zyme inhibitors, aspirin, chronic liver disease, nephropathy, cere-
brovascular disease, and chronic kidney disease. However, it was not
described whether the analysis was also adjusted for other diabetes
related covariates, for example HbA1c or BMI.
4.4. Tolbutamide
In a retrospective observational study (n=1277) with a mean
follow-up of 14 patients treated with tolbutamide had a lower cancer
mortality compared to patients treated with glibenclamide (HR 0.48,
95%CI 0.29–0.79) (Bo et al., 2013). The analyses were adjusted for
metformin and insulin use, age, sex, BMI, smoking, diabetes duration,
anti-hypertensive therapy, HbA1c, presence of retinopathy, neuropathy
and cardiovascular diseases.
4.5. Conclusions clinical evidence
In the majority of the studies described, gliclazide use was either
associated with a lower risk of developing cancer (Monami et al., 2009;
Yang et al., 2010a) or a lower risk of cancer-related mortality (Bo et al.,
2013; Monami et al., 2007) compared to other SUs or never use.
Moreover, one study showed that the reduced cancer risk in gliclazide
users was dose-dependent (Yang et al., 2010a). The majority of studies
point to a higher cancer risk and all-cancer mortality risk for glib-
enclamide users compared to T2DM patients using other SUs or never
use and this effect was also dose-dependent (Bo et al., 2013; Monami
et al., 2009, 2007; Tuccori et al., 2015). Only two studies directly
compared SUs to one another (glibenclamide vs tolbutamide and glib-
enclamide vs gliclazide (Bo et al., 2013), and glibenclamide vs glicla-
zide (Monami et al., 2007)), confirming differences in cancer-related
mortality of SUs. However, the evidence should be interpreted with
caution since all studies included were either small and grouped all
cancers together or did not account for duration or dose-response re-
lationships. Grouping cancer types might introduce bias, since certain
tissue types and malignancies may be more sensitive to effects of in-
creased blood glucose and insulin levels. Furthermore, the methodology
used in each study differed substantially; different study designs and
different statistical analyses were used. All studies adjusted for poten-
tial confounders but to a varying degree. Importantly, all included
studies corrected for at least metformin and insulin use. In case patients
used other glucose lowering agents, the analyses were either corrected
for or these patients were excluded from the study. It is uncommon to
use two different SUs at the same time, so it is unlikely that the effect
seen is influenced by concurrent SU use. Taking these limitations into
account, T2DM patients using gliclazide may have a lower cancer risk
and T2DM patients using glibenclamide may have a higher cancer risk
than T2DM patients using other SUs.
5. Preclinical evidence of the effects and working mechanisms of
SUs on cancer cells
To gain insight in possible systemic or off-target effects explaining
the different clinical cancer risks of varying SUs, available evidence of
growth inhibitory effects and potential anti-cancer mechanisms of SUs
in preclinical models of cancer is discussed in this section. This evidence
is summarized in Fig. 2. Most data are available for glibenclamide,
which is frequently used in cell line models as a pharmacological tool to
block transporters such as the potassium transporter channel. This
provides data on in vitro effects of glibenclamide on cancer cell growth
from studies not primarily designed to study SUs.
Fig. 2. Potential anti-cancer effects of sulfony-
lurea derivatives (SUs). ABC: adenosine tripho-
sphate (ATP) binding cassette transporter; Akt: pro-
tein kinase B; Chemo: chemotherapy; IGF: insulin-
like growth factor; IGFR: insulin-like growth factor
receptor; IR: insulin receptor; IKK: I-kappaB-kinase;
K+ATP: ATP-sensitive potassium channel; MMP: matrix
metalloproteinase; PI3K: phosphoinositide 3-kinase;
TNF: tumor necrosis factor; TNFR: tumor necrosis
factor receptor; VEGF: vascular endothelial growth
factor. SUs have been shown to inhibit VEGF in vitro
and in vivo resulting in impaired vasculoneogenesis
and angioneogenesis. Degradation of the extra-
cellular matrix is impaired by the SU glibenclamide
by inhibition of MMPs, which results in less pro-
liferation and invasiveness of cancer cells. Sensitivity
of cancer cells for chemotherapy might increase due
to inhibited cellular export of chemotherapeutics as a result of inhibitory effects of the SU glibenclamide on ABC transporters. The SU chlorpropamide selectively
inhibits the Akt pathway activity in cancer cells, resulting in cell growth arrest and apoptosis of cancer cells in vitro and in vivo. SUs have also been shown to inhibit
TNF and TNFR levels in cancer cells, which might have pro-cell death effects. Inhibition of K+ATP by SUs reduces cancer cell growth in vitro and in vivo, possibly by
inducing apoptosis.
A.M. Hendriks, et al. European Journal of Pharmacology 861 (2019) 172598
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5.1. Effect of SUs on cancer cell growth
Glibenclamide inhibited growth of human prostate (Abdul and
Hoosein, 2002a), hepatocellular (Kim et al., 1999; Malhi et al., 2000;
Zhou et al., 2003), breast (Nunez et al., 2013; Woodfork et al., 1995),
gastric (Qian et al., 2008), bladder (Wondergem et al., 1998), glioma
(Ru et al., 2014) and colon (Abdul and Hoosein, 2002b) cancer cell lines
in vitro. In human prostate, glioma and colon cancer cells this effect was
dose-dependent and occurred at doses around 0.1mM (50 μg/mL)
(Abdul and Hoosein, 2002a, Abdul and Hoosein, 2002b; Ru et al.,
2014), which is at least 100 fold higher than the plasma concentrations
achieved clinically in daily practice with doses used in T2DM patients
(Coppack et al., 1990). In bladder and breast cancer cells, reduced
cellular proliferation has also been reported to be dose-dependent and
was seen at concentrations which did not differ greatly from clinically
achievable plasma concentrations (Wondergem et al., 1998; Woodfork
et al., 1995). In human ovarian cancer cell line models, cell growth was
not inhibited by glibenclamide (Han et al., 2007; Zhanping et al.,
2007). Proliferation of glioma cells was inhibited by 7 days tolbutamide
treatment at 100 μM (Huang et al., 2009), this is about 2600 times the
clinically achievable range of tolbutamide plasma concentrations
(Andreasen and Vesell, 1974).
Glipizide, but not glimepiride, suppressed tumor growth and me-
tastases in vivo in breast cancer and melanoma xenografts and in
transgenic mouse models of breast cancer (Qi et al., 2014). The doses of
glipizide and glimepiride used in the study resulted in concentrations
consistent with clinically achievable plasma concentrations (Simonson
et al., 1997).
In general, it appears that in certain conditions, treatment with
glibenclamide can reduce growth of cancer cells. However, in the ma-
jority of studies only one or two cancer cell lines were studied and
glucose concentration of cell culture media used varied widely or were
not mentioned. No studies compared the influence of glibenclamide on
cell growth in a large range of different cell lines in the same conditions.
Furthermore, the potential mechanisms of growth inhibition of glib-
enclamide are not elucidated. Therefore, the results should be inter-
preted with caution and effects and mechanisms may be cell line spe-
cific. The possible mechanisms by which SUs might influence cancer
development are discussed in the following paragraphs.
5.2. Effects of SUs on growth factors and growth factor pathways
Insulin and insulin-like growth factor (IGF) have been shown to
stimulate cancer cell proliferation. Exposing a human neuroblastoma
cell line to glibenclamide resulted in an increase of mRNA expression of
insulin and IGF-1 receptors (Ota et al., 1989). This resulted in increased
binding of insulin and IGF-1 to the neuroblastoma cells, but not in in-
creased glucose uptake. Only short-term experiments, up to 24 h
duration, were described. Studies with longer drug incubation times are
required to determine whether this results in enhanced cancer cell
growth.
Gliclazide inhibited levels of tumor necrosis factor (TNF) production
by human peripheral blood mononuclear cells and inhibited TNF
bioactivity and immunoreactivity in mouse serum (Desfaits et al., 1998;
Fukuzawa et al., 1999; Qiang et al., 1998). Chlorpropamide inhibited
levels of TNF receptors in peripheral blood mononuclear cells (Nunes
et al., 2004). TNF is a cytokine, which can have both pro-survival and
pro-cell death effects, mediated through the TNF receptors. More de-
tailed mechanistic studies are required to determine how different SUs
influence this delicate balance in cancer cells.
The protein kinase B (Akt) pathway is a signaling pathway, often
activated in cancer and downstream of the insulin receptor. This
pathway is involved in many cellular processes, including cell survival,
cell cycle progression and cellular growth (Fresno Vara et al., 2004). A
chlorpropamide analogue API-2 selectively inhibited the Akt pathway
activity in cancer cells with elevated Akt expression without influencing
other pathways, resulting in cell growth arrest and apoptosis of cancer
cells in vitro and in vivo (Yang et al., 2004). This is of interest since the
Akt pathway is hyperactivated in many cancer types and therefore an
attractive therapeutic target. However, clinical development of such
inhibitors has been hampered by drug-toxicity (Mundi et al., 2016).
5.3. Effects of SUs on ATP-binding cassette transporters and solute channels
Sulfonylurea receptors belong to the ATP-binding cassette trans-
porter superfamily, which are transmembrane proteins that transport
substrates across cellular membranes. Multidrug-resistance proteins
(MRPs) are ATP-binding cassette transporters involved in the cellular
export of several drugs, including chemotherapeutic drugs, and can
therefore protect cancer cells from anti-cancer drugs (Lautier et al.,
1996). Glibenclamide is an inhibitor of various ATP-binding cassette
transporter proteins (Golstein et al., 1999; Hamon et al., 1997;
Sheppard and Robinson, 1997; Stieger et al., 2000). Glibenclamide in-
hibited MRP1 in human lung cancer cells resulting in enhanced sensi-
tivity of these cells to the anti-cancer drug and MRP substrate vincris-
tine (Payen et al., 2001). However, in this study, the dose of
glibenclamide required for this effect was at least 10-fold higher than
the therapeutic plasma concentration currently achieved clinically
(Coppack et al., 1990). Glibenclamide also inhibited the transport of the
drug alpha-tocopheryl-phosphate across the cell membrane into cells in
a leukemia cell line, thereby reducing the anti-proliferative effect of this
drug (Negis et al., 2007). However, the transporter involved was not
identified. If this effect is indeed confirmed at physiological doses for
certain drug transporters then caution may be required when glib-
enclamide use is combined with anti-cancer drugs. However, although
the efficacy of efflux pump inhibitors to improve the effect of che-
motherapeutics has been extensively studied clinically, results have so
far been disappointing (Ughachukwu and Unekwe, 2012).
Some potassium channels are regulated by sulfonylurea receptors
and can be (potently) inhibited by, for example, glibenclamide (Burke
et al., 2008; Reeve et al., 1992; Zhou et al., 2003). Deregulated ex-
pression of all four classes of potassium channels has been demon-
strated in human cancers and overexpression has been correlated with
increased cell proliferation (Hemmerlein et al., 2006; Huang and Jan
2014; Pardo and Stuhmer, 2008; Wang, 2004). Pharmacological in-
hibition of potassium channels has been shown to reduce cancer cell
growth in vitro and in vivo in cancers with overexpression of these
channels (Downie et al., 2008). Voltage-gated potassium channels were
blocked by glibenclamide in a hepatocellular carcinoma cell line, re-
sulting in reduced proliferation (Zhou et al., 2003). However, in an-
other study, no effect was seen in an ovarian cancer cell line (Zhanping
et al., 2007). Potassium channel blockers mediate depolarization of
membranes; this can result in programmed cell-death (apoptosis) and
therefore this may also be expected for SUs. Indeed, induction of
apoptosis by glibenclamide was described in several human cancer cell
line models (Abdul and Hoosein, 2002a; Kim et al., 1999; Qian et al.,
2008; Ru et al., 2014; Suzuki et al., 2012; Yan et al., 2017). In addition,
both glibenclamide and tolbutamide enhanced apoptosis induced by
other drugs (Mohapatra et al., 2009; Paíno et al., 2010). In contrast,
gliclazide protected cancer cells from hydrogen peroxide induced
apoptosis (Kimoto et al., 2003; O'Brien et al., 2000; Sliwinska et al.,
2012). In general, it appears that influence of glibenclamide on po-
tassium channels and apoptosis is likely to be dose dependent and po-
tentially cell-line dependent.
5.4. Effects of SUs on angiogenesis and metastasis
Angiogenesis plays a major role in cancer progression and metas-
tasis, and is mediated by growth factors such as vascular endothelial
growth factor (Gu et al., 2015). Inhibition of neovascularization can be
useful as anti-cancer therapy by controlling tumor growth and metas-
tasis. Bevacizumab, a monoclonal anti-body against vascular
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endothelial growth factor A, and several tyrosine kinase inhibitors with
anti-angiogenic properties are registered as anti-cancer therapy in se-
lected tumor types.
Glibenclamide inhibited cellular invasion and migration in a human
ovarian cancer cell line model through inhibition of components of the
angiogenic pathway (Yasukagawa et al., 2012). In vivo studies in early
chick embryo chorioallantoic membrane and yolk sac membrane
models and in prostate cancer mouse models showed that glipizide also
inhibited vasculoneogenesis and angioneogenesis (Gu et al., 2015; Qi
et al., 2016, 2014).
Degradation of the extracellular matrix is essential for tumor inva-
sion and metastasis. Among the essential proteins for this process of
degradation are various types of matrix metalloproteinase. Growth,
proliferation and invasiveness of breast cancer in TA2 mice was in-
hibited by a combined treatment of glibenclamide and cobalt chloride
through inhibition of matrix metalloproteinases (Rong et al., 2013). In
contrast, in ovarian cancer cells, glibenclamide had no effect on cell
adhesion, cell invasion or migration (Li et al., 2009). Lymphatic spread
is frequently a first step in cancer metastasis. Acetohexamide dose-de-
pendently inhibited breast cancer intravasation into lymph ducts in a
three-dimensional cell co-culture assay (Kretschy et al., 2013). This
effect of acetohexamide was identified during a screening procedure of
hundreds of drugs registered for non-cancer indications. This observa-
tion is yet to be confirmed in other in vitro and in vivo cancer models and
the exact mechanism has not been elucidated.
5.5. The effects of SUs on anti-cancer treatment
SUs might not only affect cancer initiation and progression but also
the efficacy of anti-cancer treatment. Glibenclamide has been shown to
protect human glioblastoma, primary astrocytes and normal lung tissue
cell lines from radiation-induced cell death (Jiang et al., 2009). Mice
injected with glibenclamide before total body irradiation lived longer
compared to mice injected with glibenclamide after radiation therapy
or without glibenclamide treatment (Jiang et al., 2009). The specific
underlying mechanisms of the radio-protective effect of glibenclamide
pre-administration are unknown (Jiang et al., 2009). Furthermore, in
liver and lung cancer cell lines glibenclamide has been shown to in-
crease the cytotoxicity of the chemotherapeutic drug doxorubicin
(Subramaniyam et al., 2018). This study showed altering DNA con-
formation effects of glibenclamide possibly explaining its synergistic
effects on doxorubicin treatment (Subramaniyam et al., 2018).
Analogues of chlorpropamide inhibited human aldehyde dehy-
drogenase 3 (ALDH-3) in cancer cells and sensitized breast cancer cells
to chemotherapy (Rekha et al., 1998; Sládek et al., 2001). ALDH-3 can
be overexpressed in cancer cells and is involved in detoxification of
certain types of chemotherapy and may therefore be involved in re-
sistance to these therapies. Thus, inhibition of ALDH-3 is of interest to
enhance tumor sensitivity to these chemotherapeutic drugs, however
this has yet to be investigated in in vivo models.
Cancer cell resistance to chemo- and radiotherapy is, among others,
enhanced by upregulation of the Akt-pathway (Shimura et al., 2014;
Yang et al., 2010b). A chlorpropamide analogue, API-2, inhibited this
pathway and reduced chemo- and radioresistance (Shimura et al., 2014;
Williams et al., 2012; Yang et al., 2010b). Furthermore, API-2 sensitized
immune resistant tumors for CD8+ T-cell mediated apoptosis by Akt
inhibition and might therefore improve immunotherapy (Noh et al.,
2009). API-2 can induce either apoptosis or metastasis depending on
the nuclear β-catenin expression, which differs between cancer cells
suggesting pleiotropic effects of API-2 (Tenbaum et al., 2012). It is
unknown whether use of chlorpropamide itself results in the same ef-
fects.
The preclinical evidence suggests numerous potential anti-cancer
mechanisms of SUs. However, systemic studies in cancer cell line panels
and relevant model systems at clinically achievable drug concentrations
are lacking.
6. Discussion
The overall clinical evidence suggests that the influence of SUs on
cancer risk in T2DM patients differs between the various SUs. Potential
mechanisms include differing affinities for the sulfonylurea receptors
resulting in differential systemic insulin exposure and off-target anti-
cancer effects mediated for example through potassium transporters or
drug export pumps.
Observational studies demonstrated that the use of the second
generation SU gliclazide was associated with a lower risk of developing
cancer compared to never use of gliclazide (Monami et al., 2009; Yang
et al., 2010a). Gliclazide users also had a lower risk of cancer-related
mortality compared to glibenclamide users (Bo et al., 2013; Monami
et al., 2007). Glibenclamide use was associated with a higher risk of
developing cancer compared to other second generation SUs and to no
use of glibenclamide (Monami et al., 2009; Tuccori et al., 2015). All
studies had important methodological limitations and used different
study designs and statistical methods. Interpretation of results and di-
rect comparisons of the retrospective clinical studies were hampered by
low numbers of cancer cases, grouping together of different cancer
types and lack of data on dose or cumulative exposure of SUs.
Higher insulin levels have tumor promoting effects in vitro in cell
line models, in vivo in animal models and in human epidemiological
studies (Ariaans et al., 2015). Metformin reduces peripheral insulin
resistance resulting in lower blood insulin and glucose levels (Fig. 3).
This could, at least in part, explain the potential anti-cancer effects of
this drug (Jalving et al., 2010; Soranna et al., 2012). The different ef-
fects of gliclazide and glibenclamide on cancer risk and mortality may
also be explained by differential influences on blood insulin levels of
both agents (Fig. 3). Glibenclamide has been associated with an in-
creased and pro-longed hypoglycaemia risk compared to other SUs.
This can be explained by the relatively long half-life time of glib-
enclamide due to high affinity for the sulfonylurea receptor 1 and the
slow reversibly of the sulfonylurea receptor 1 binding (Gribble and
Reimann, 2003b; Melander, 2004). The accumulation of active meta-
bolites due to impaired renal function may also contribute to the hy-
poglycaemia risk of glibenclamide (Arnouts et al., 2014; Gangji et al.,
2007; Harrower, 2000). Glibenclamide is not selective for just sulfo-
nylurea receptor 1 located on the pancreatic β-cells of the pancreas, but
also binds sulfonylurea receptor 2A and B which are widely expressed,
amongst others, on cardiac muscle (Gribble and Reimann, 2003b; Seino
et al., 2012). In contrast, gliclazide binds more selectively with rapid
reversibility to sulfonylurea receptor 1 located on pancreatic β-cells
(Gribble and Reimann, 2003b; Seino et al., 2012) and is hepatically
metabolised into inactive metabolites before renal elimination (The
electronic Medicines Compendium, n.d.).
SUs with the most selective meal dependent insulin release are ex-
pected to be associated with the lowest cancer risks due to lower overall
insulin exposure and this may explain the observed clinical differences.
Differential insulin responses of glibenclamide and gliclazide have in-
deed been demonstrated. The physiological pancreatic insulin response
is biphasic, the first phase concerns rapid insulin exocytosis within
5–10min after stimulation whereas the second phase can sustain for
hours in case of persisting elevated glucose levels (Wang and
Thurmond, 2009). In an in vitro model measuring insulin release in
isolated rat pancreases, a biphasic insulin response to gliclazide treat-
ment was demonstrated which was in contrast to the delayed mono-
phasic insulin response to glibenclamide treatment (Gregorio et al.,
1992). In two small randomized double-blind trials, containing 24 and
12 patients respectively, glibenclamide was shown to have a stimula-
tory effect on the second but not on the first phase of insulin secretion
(Cozma et al., 2002; Ligtenberg et al., 1997). Furthermore, in-
appropriate insulin secretion in case of low blood glucose levels has
been shown in T2DM patients and healthy volunteers using glib-
enclamide (Draeger et al., 1996; Hollander et al., 2001; Riefflin et al.,
2015; Szoke et al., 2006). The biphasic glucose-dependent insulin
A.M. Hendriks, et al. European Journal of Pharmacology 861 (2019) 172598
7
response of gliclazide was confirmed in four diabetic patients and four
healthy controls (Chiasson et al., 1991). In conclusion, gliclazide ap-
pears to result in a selective glucose dependent insulin release which in
turn results in a more physiological insulin response and a corre-
sponding lower average blood insulin level than for example glib-
enclamide (Fig. 3).
Preclinical studies suggest that SUs could have direct inhibitory
effects on cancer cell growth (Abdul and Hoosein, 2002a, Abdul and
Hoosein, 2002b; Kim et al., 1999; Malhi et al., 2000; Nunez et al., 2013;
Qian et al., 2008; Ru et al., 2014; Wondergem et al., 1998; Woodfork
et al., 1995; Zhou et al., 2003). Especially glibenclamide had anti-
proliferative effects in some preclinical cancer models, potentially
through blockade of potassium channels thus inducing apoptosis (Abdul
and Hoosein, 2002a, Abdul and Hoosein, 2002b; Golstein et al., 1999;
Hamon et al., 1997; Kim et al., 1999; Malhi et al., 2000; Nunez et al.,
2013; Qian et al., 2008; Ru et al., 2014; Sheppard and Robinson, 1997;
Stieger et al., 2000; Wondergem et al., 1998; Woodfork et al., 1995;
Zhou et al., 2003). However, glibenclamide is often studied due to its
pharmacological effect on the potassium channels and not system-
atically with the goal of studying the anti-cancer effects of the drug. No
large systematic comparison of growth inhibitory effects of the different
SUs in panels of cancer cell lines have been performed. Furthermore,
thorough investigation of effects of SUs on signal-transduction routes
important to cancer cell growth have not been performed, and no stu-
dies on cancer cell metabolism were identified. Extra-pancreatic, organ
specific effects of SUs on glucose metabolism exist and may differ be-
tween individual SUs as has been described for glibenclamide and gli-
mepiride (Beck-Nielsen et al., 1988; Feldman and Lebovitz, 1969;
Müller et al., 1995). The anti-cancer effects of SUs may be considered a
novel extra-pancreatic effect. There is insufficient data available to
determine whether the anti-cancer effects of SUs are correlated to their
known extra-pancreatic effects on glucose metabolism.
The reported concentrations of SUs used in the reviewed in vitro
studies appear to be high compared to the achievable therapeutic range
in patients, which is measured as total (free plus protein-bound) plasma
concentrations. Several factors complicate interpretation of these re-
ported in vitro concentrations. Firstly, SUs bind to proteins in the cell
culture medium (Hsu et al., 1974; Proks et al., 2018; Seedher and
Kanojia, 2009, 2008) and, therefore, the actual free drug concentration
available at the target may be lower than the reported SU concentra-
tion. Consequently, it is unknown at which actual drug concentrations
the described anti-cancer effects of SUs at the cellular levels occurred.
Secondly, SU binding affinities to albumin used for cell culture versus
human albumin differ and SUs may bind to other proteins than only
albumin (Proks et al., 2018). Thus translation of the in vitro data is
seriously hampered due to the probable differing degrees of protein
Fig. 3. Schematic representation of
blood insulin and glucose interactions in
relation to oral glucose lowering agents.
GLUT-4: glucose transporter 4; IR: insulin
receptor; T2DM: type 2 diabetes mellitus.
A) In non-diabetic patients, binding of in-
sulin to peripheral tissues leads to translo-
cation of glucose transporter 4 (GLUT-4) to
the cell membrane enabling glucose influx.
Glucose stimulates insulin excretion by β-
cells of the pancreas. Insulin inhibits glu-
coneogenesis by the liver. B) In T2DM pa-
tients, peripheral tissues and liver tissue are
insulin resistant. This results in hypergly-
cemia due to reduced cellular influx of
glucose, increased insulin secretion by β-
cells of the pancreas and stimulation of
gluconeogenesis. C1) T2DM patients suffer
from hyperglycemia and hyperinsulinemia.
C2) Gliclazide treatment results in a slightly
higher basal blood insulin level than in un-
treated T2DM patients and in a selective
glucose-dependent insulin release. C3)
Glibenclamide results in a less specific glu-
cose-dependent insulin release than glicla-
zide, resulting in higher basal blood insulin
levels and prolonged insulin secretion after
a meal. C4) Metformin reduces insulin re-
sistance of peripheral tissues and liver tissue
resulting in less insulin secretion.
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binding between in vitro models and patients. Furthermore, there are
multiple factors besides protein binding that determine the free drug
concentrations surrounding the therapeutic target in the tumor in pa-
tients (Smith et al., 2010).
Clinical and preclinical data are conflicting regarding influence of
glibenclamide on cancer risk and development. This is likely due to
differential systemic versus intra-cellular effects of SUs. The association
of glibenclamide use and increased cancer risk may be explained by the
relatively high insulin exposure during glibenclamide treatment com-
pared to other SUs. This is clearly not compensated by cancer inhibiting
effects at the cellular level in patients. The preclinically described po-
tential anti-cancer effects of SUs are of interest from a mechanistic point
of view and deserve further investigation. This may result in novel anti-
cancer drug targets and/or potential repurposing of SUs.
In conclusion, it appears that T2DM patients using gliclazide may
have a lower cancer risk than those using glibenclamide. However, the
evidence on differences in cancer risk between the different SUs and SU
classes is, at this time, not strong enough to guide clinical decision-
making.
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